GRAIL, Inc. is facing a proposed securities class action alleging it misled investors about the state of its NHS-Galleri trial and the likelihood that the study could demonstrate a statistically significant reduction in late-stage cancers within its three-year follow-up period. The proposed class covers investors who purchased or acquired GRAIL common stock between May 13, 2025 and Feb. 19, 2026, with an Aug. 4, 2026 deadline to apply to be appointed lead plaintiff. The complaint alleges the company made materially false and misleading statements or concealed adverse facts after revealing top-line results from the trial’s first screening round. It claims defendants later acknowledged that, as executed within the three-year follow-up period, the trial was insufficient to show whether the primary endpoint of reducing Stage III-IV cancers was achievable, while repeatedly declining to provide more detailed topline results or other NHS-Galleri data. On Feb. 19, 2026, GRAIL announced results from the NHS-Galleri trial evaluating annual multi-cancer screening with its Galleri test, stating that the primary endpoint of statistically significant Stage III-IV reduction was not observed. The lawsuit contends that disclosure exposed the limits of the trial design and triggered a significant drop in GRAIL’s stock price.